Prelude Therapeutics (NASDAQ:PRLD) Trading Down 0.9% – Here’s What Happened

Prelude Therapeutics Incorporated (NASDAQ:PRLD)’s stock price traded down 0.9% during mid-day trading on Monday . The stock traded as low as $2.04 and last traded at $2.15. 202,870 shares were traded during trading, a decline of 52% from the average session volume of 426,020 shares. The stock had previously closed at $2.17.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on PRLD shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prelude Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen lowered Prelude Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, January 18th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $4.00.

Prelude Therapeutics Stock Performance

The stock has a market capitalization of $135.17 million, a PE ratio of -1.46 and a beta of 0.88. The business’s 50-day moving average price is $2.12 and its 200 day moving average price is $1.58.

Prelude Therapeutics (NASDAQ:PRLD) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.09. The business had revenue of $6.50 million for the quarter. As a group, equities research analysts predict that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC raised its stake in Prelude Therapeutics by 170.7% in the first quarter. AQR Capital Management LLC now owns 33,823 shares of the company’s stock valued at $26,000 after purchasing an additional 21,330 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Prelude Therapeutics in the 2nd quarter worth $34,000. XTX Topco Ltd raised its position in shares of Prelude Therapeutics by 72.4% during the 2nd quarter. XTX Topco Ltd now owns 42,573 shares of the company’s stock valued at $34,000 after buying an additional 17,873 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of Prelude Therapeutics during the 2nd quarter worth $39,000. Finally, Shay Capital LLC purchased a new position in Prelude Therapeutics in the second quarter worth $61,000. 79.72% of the stock is currently owned by institutional investors.

About Prelude Therapeutics

Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude’s pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.

Among Prelude’s lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations.